Vitamin D: An innate antiviral agent suppressing hepatitis C virus in human hepatocytes

Hepatology

Volumn 54, Issue 5, 2011, Pages 1570-1579

  Gal Tanamy, Meital ^a   Bachmetov, Larisa ^a   Ravid, Amiram ^a   Koren, Ruth ^a   Erman, Arie ^b   Tur Kaspa, Ran ^a,b   Zemel, Romy ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; CALCITRIOL; COLECALCIFEROL; CYTOCHROME P450; CYTOCHROME P450 24A1; CYTOCHROME P450 27B1; MYXOVIRUS RESISTANCE PROTEIN A; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; GENE INDUCTION; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS INFECTIVITY; VIRUS INHIBITION; VITAMIN D METABOLISM;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANTIVIRAL AGENTS; CALCITRIOL; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHOLECALCIFEROL; DRUG SYNERGISM; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; SIGNAL TRANSDUCTION; STEROID HYDROXYLASES; VITAMINS;

EID: 80055060055     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24575     Document Type: Article

References (40)

1. Georgel P, Schuster C, Zeisel MB, Stoll-Keller F, Berg T, Bahram S, et al. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med 2010; 16: 277-286.
2. Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010; 36: 91-133.
3. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463.
4. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-972.
5. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277: F157-175.
6. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-687.
7. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 2624-2628.
8. Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 2010; 70: 1448-1460.
9. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28.
10. Hewison M, Zehnder D, Bland R, Stewart PM. 1alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol 2000; 25: 141-148.
11. Fleet JC, Hong J, Zhang Z. Reshaping the way we view vitamin D signalling and the role of vitamin D in health. Nutr Res Rev 2004; 17: 241-248.
12. Li J, Fleet JC, Teegarden D. Activation of rapid signaling pathways does not contribute to 1alpha, 25-dihydroxyvitamin D3-induced growth inhibition of mouse prostate epithelial progenitor cells. J Cell Biochem 2009; 107: 1031-1036.
13. Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 2002; 22: 139-166.
14. Zierold C, Mings JA, DeLuca HF. Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1, 25-dihydroxyvitamin D3 and parathyroid hormone. J Cell Biochem 2003; 88: 234-237.
15. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004; 79: 362-371.
16. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79: 820-825.
17. Chesney RW. Vitamin D and the magic mountain: the anti-infectious role of the vitamin. J Pediatr 2010; 156: 698-703.
18. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol 2011; 50: 194-200.
19. Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11: 1843-1847.
20. Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007; 5: 513-520.
21. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. HEPATOLOGY 2010; 51: 1158-1167.
22. Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011; 24: 43-50.
23. Schauber J, Gallo RL. The vitamin D pathway: a new target for control of the skin's immune response? Exp Dermatol 2008; 17: 633-639.
24. Sun J. Vitamin D and mucosal immune function. Curr Opin Gastroenterol 2010; 26: 591-595.
25. Yi M, Ma Y, Yates J, Lemon SM. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 2007; 81: 629-638.
26. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002; 76: 13001-13014.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
28. Bourne N, Pyles RB, Yi M, Veselenak RL, Davis MM, Lemon SM. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system. Antiviral Res 2005; 67: 76-82.
29. Cheng G, Zhong J, Chisari FV. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. Proc Natl Acad Sci U S A 2006; 103: 8499-8504.
30. Saati N, Ravid A, Liberman UA, Koren R. 1, 25-dihydroxyvitamin D3 and agents that increase intracellular adenosine 3', 5'-monophosphate synergistically inhibit fibroblast proliferation. In Vitro Cell Dev Biol Anim 1997; 33: 310-314.
31. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 2008; 1143: 1-20.
32. Li K, Chen Z, Kato N, Gale M Jr, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 2005; 280: 16739-16747.
33. Smith PL, Lombardi G, Foster GR. Type I interferons and the innate immune response-more than just antiviral cytokines. Mol Immunol 2005; 42: 869-877.
34. Hiscott J. Triggering the innate antiviral response through IRF-3 activation. J Biol Chem 2007; 282: 15325-15329.
35. Hansdottir S, Monick MM, Lovan N, Powers L, Gerke A, Hunninghake GW. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. J Immunol 2010; 184: 965-974.
36. Bitetto D, Fabris C, Falleti E, Fornasiere E, Fumolo E, Fontanini E, et al. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int 2010; 30: 417-444.
37. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559-568.
38. Zierold C, Mings JA, DeLuca HF. Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1, 25-dihydroxyvitamin D3 and parathyroid hormone. J Cell Biochem 2003; 88: 234-237.
39. Bar-Shavit Z, Noff D, Edelstein S, Meyer M, Shibolet S, Goldman R. 1, 25-dihydroxyvitamin D3 and the regulation of macrophage function. Calcif Tissue Int 1981; 33: 673-676.
40. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am 2010; 39: 365-379.